Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.
Martinez
Steve R
SR
Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, California 90404, USA.
Hoon
Dave S B
DS
D015415:Biomarkers; D017024:Chemotherapy, Adjuvant; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D006801:Humans; D008545:Melanoma / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D009154:Mutation; D009362:Neoplasm Metastasis; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome
D015415:Biomarkers